REGULATED PRESS RELEASE published on 04/08/2024 at 23:10, 1 year 9 months ago Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone) Biophytis lance l'étude clinique de phase 2 OBA pour traiter l'obésité avec BIO101 (20-hydroxyecdysone), visant à préserver la masse musculaire. Programme ayant des résultats prometteurs, début de l'étude prévu mi-2024 Biophytis Étude Clinique BIO101 Obésité OBA
PRESS RELEASE published on 04/08/2024 at 23:04, 1 year 9 months ago Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités. Découvrez les principaux faits marquants et perspectives pour 2024 ainsi que les éléments financiers clés de l'année 2023 Biophytis Biotechnologie Développement Clinique Résultat Annuel Santé
PRESS RELEASE published on 04/08/2024 at 23:04, 1 year 9 months ago Biophytis announces its 2023 financial results and provides an update on its business activities Biophytis announces 2023 financial results & updates business activities. Successfully developing clinical programmes & obtaining FDA approval for SARA-31 trial in sarcopenia Biophytis FDA Approval 2023 Financial Results Clinical Programmes SARA-31 Trial
PRESS RELEASE published on 04/08/2024 at 23:01, 1 year 9 months ago Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) Biophytis annonce ses résultats financiers 2023 et lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone), confirmant son avancement dans le développement de traitements innovants Biophytis Résultat Annuel Étude Clinique BIO101 Obésité
PRESS RELEASE published on 04/08/2024 at 23:01, 1 year 9 months ago Biophytis announces its 2023 financial results and provides an update on its business activities Biophytis announces 2023 financial results & business update. Highlights: progress in clinical programmes, funding secured till 2025. Key focus on SARA, OBA, COVA, OBA, and MYODA programs Financial Results Biophytis 2023 Funding Clinical Programmes
PRESS RELEASE published on 04/08/2024 at 23:00, 1 year 9 months ago Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) Biophytis launches OBA phase 2 clinical study with BIO101 (20-hydroxyecdysone) for obesity treatment, targeting muscle preservation and promising results. Clinical program expected to start mid-2024 Biophytis Obesity Treatment BIO101 OBA Phase 2 Muscle Preservation
PRESS RELEASE published on 04/08/2024 at 23:00, 1 year 9 months ago Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone) Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone). Résultats prometteurs pour traiter la perte musculaire liée à l'obésité. Marché potentiel de 100 milliards de dollars d'ici 2030 Biophytis Étude Clinique BIO101 Obésité Perte Musculaire
PRESS RELEASE published on 04/08/2024 at 23:00, 1 year 9 months ago Medicure Reports Financial Results for Quarter and Year Ended December 31, 2023 Medicure Inc. reports results from operations for the quarter and year ended December 31, 2023. Net revenue, EBITDA, and financial highlights disclosed Financial Results EBITDA Quarterly Report Medicure Inc. Revenue Analysis
PRESS RELEASE published on 04/08/2024 at 23:00, 1 year 9 months ago Board-Certified and Highly Accomplished, Active Duty Military Ophthalmologist Now Treating Patients at LasikPlus Louisville Kentucky-based ophthalmologist Dr. Gregory Bryant Giles, known for his expertise in LASIK and cataract surgery, is now treating patients at LasikPlus Louisville vision center LASIK Dr. Gregory Bryant Giles Cataract Surgery Ophthalmology LasikPlus
PRESS RELEASE published on 04/08/2024 at 23:00, 1 year 9 months ago E-PASS Customers Can Save on Monthly Bill as Part of State’s Toll Relief Program E-PASS customers can now save 50% on monthly toll bills starting April 1, thanks to the statewide toll relief program announced by Gov. Ron DeSantis. Discounts applicable to two-axle vehicles with 35+ trips monthly Savings Florida Discounts E-PASS Toll Relief Program
Published on 01/16/2026 at 22:30, 27 minutes ago Usha Resources and Totec Resources Complete Concurrent Financing for Gross Proceeds of $4,500,000
Published on 01/16/2026 at 15:25, 7 hours 32 minutes ago Silver North Announces Upsize of Brokered LIFE Private Placement for Gross Proceeds of up to C$7.0 Million
Published on 01/16/2026 at 14:00, 8 hours 57 minutes ago GameSquare to Present at the Sequire Investor Summit on January 20-22, 2026
Published on 01/16/2026 at 14:00, 8 hours 57 minutes ago CCL Industries Signs Agreement to Acquire ALT Technologies for CCL Design
Published on 01/16/2026 at 13:45, 9 hours 12 minutes ago Quartz Mountain Expands Maestro Project With Claim Acquisition
Published on 01/16/2026 at 19:07, 3 hours 49 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/16/2026 at 18:36, 4 hours 21 minutes ago CPI PROPERTY GROUP – Completion of the Share Buy-back Offer
Published on 01/16/2026 at 18:12, 4 hours 45 minutes ago Westwing Group SE Trading Update: Westwing delivered a strong 9% GMV growth in Q4 2025 and significantly increased full-year 2025 guidance on adjusted EBITDA
Published on 01/16/2026 at 18:00, 4 hours 57 minutes ago ROCTOOL: INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 01/16/2026 at 18:39, 4 hours 17 minutes ago Nombre total d'actions et droits de vote - décembre 2025
Published on 01/16/2026 at 18:39, 4 hours 17 minutes ago Number of shares and voting rights - December 2025 (In French only)
Published on 01/16/2026 at 17:45, 5 hours 12 minutes ago Half yearly report on the liquidity contract
Published on 01/16/2026 at 08:53, 14 hours 3 minutes ago www.entech-se.com COMMUNIQUÉ DE PRESSE Entech remporte un contrat pour la construction de 400 MWh de stockage d’énergie (BESS) en partenariat avec Eiffage Énergie Systèmes